梭杆菌
生物
普雷沃菌属
鼻咽癌
互惠主义(生物学)
转录组
亚临床感染
免疫学
生物标志物
微生物学
梭杆菌门
微生物群
呼吸道感染
重编程
主机响应
计算生物学
免疫疗法
基因
上皮内淋巴细胞
疾病
细菌遗传学
TSC1
细胞
呼吸道
作者
Ying-Qi Lu,Jia-Hao Dai,Yu-Fei Duan,Guan-Jie Qin,Sai-Wei Huang,Li Lin,Xi-Rong Tan,Xun-Hua Zhu,Qing-Mei He,Jing-Yun Wang,Mei-Yin Zhang,Sen-Yu Feng,Shi-Wei He,Nan Si,Jia-Qi Wu,Guan-Lin Lv,Ye-Lin Liang,Jun-Yan Li,Sha Gong,Ying-Qin Li
标识
DOI:10.1126/scitranslmed.aec4847
摘要
The nasopharynx constitutes a critical niche in the upper respiratory tract, harboring a diverse microbiota linked to nasopharyngeal carcinoma (NPC), the mechanistic roles of which remain poorly understood. Here, we established the Nasopharyngeal Mucosal and Tumor-resident Bacterial Catalog (NMTBC) that comprises 5311 bacterial isolates representing 127 species, with 1006 of them being fully sequenced and annotated, providing a comprehensive culturable resource facilitating mechanistic dissection of the microbiome-tumor interactions. With NMTBC, we uncovered a Fusobacterium - Prevotella mutualism and revealed heterotypic bacterium-bacterium interactions involving transcriptional reprogramming and metabolic cross-talk. Using single-bacterial transcriptomics, we mapped a high-resolution transcriptomic trajectory, showing the ability of a single strain to differentiate into functionally distinct subpopulations that cooperate to sustain mutualism. By analyzing a multicenter NPC cohort, we showed that Fusobacterium and Prevotella co-colonization in NPC tumors correlated with unfavorable clinical outcomes after conventional radiochemotherapy. Analysis of RNA-seq data from two previous phase 3 clinical trials showed that coenrichment of Fusobacterium - Prevotella predicted better response to anti–PD-1 immunotherapy, highlighting their important role in microbiota-mediated immunomodulation. Overall, this study establishes a comprehensive nasopharyngeal bacterial catalog through culturomics, which offers valuable insights into microbiome-derived biomarker discovery and immunotherapy patient stratification in clinical practice.
科研通智能强力驱动
Strongly Powered by AbleSci AI